Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Key claim: A clinical trial is testing the safety and efficacy of preemptive CIML NK cell infusions expanded with IL-2 after allogeneic stem cell transplant to prevent relapse in AML, MDS, and MDS/MPN overlap syndrome.
Abstract
The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or MDS and myeloproliferative neoplasm (MPN) overlap syndrome after a standard-of-care stem cell transplant.
Names of the study therapies involved in this study are:
- CIML NK cells intravenous infusion (cellular therapy)
- Subcutaneous Interleukin-2 (recombinant, human glycoprotein)
Why this matters
This finding doesn’t shift the upstream decision of whether/when to transplant, but it expands the post-transplant relapse-prevention toolkit by testing CIML NK cells in a preemptive rather than salvage setting — relevant for MDS/MPN overlap patients who do proceed to allo-HSCT. If successful, it would sit alongside HMA and pegINFa maintenance as another modality that could make transplant outcomes more durable, indirectly strengthening the case for earlier referral in borderline candidates.